Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 19 for Polycystic kidney disease

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

    Jacksonville, FL, Rochester, MN

  2. PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

    Jacksonville, FL

  3. A Study of Quality of Life and Pain Control Before and After Endovascular Renal Denervation in Individuals with Refractory Kidney Pain

    Rochester, MN

  4. Evaluation of 18F-Sodium Fluoride Positron Emission Tomography and Diffusion Magnetic Resonance Imaging to Assess Baseline Differences Between Autosomal Dominant Polycystic Kidney Disease and Healthy Subjects, and Disease Progression in Adults with ADPKD

    Rochester, MN

  5. A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    Rochester, MN

  6. A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

    Rochester, MN

  7. A Study to Evaluate the Intrarenal Microvessels in Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

  8. A Study to Analyze Metabolic Fingerprinting in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Controls

    Rochester, MN

  9. Study to Evaluate Clinical Complications, Pattern of Kidney Function Decline and Identification of Clinical Variables Related to Progression of Autosomal Dominant Polycystic Kidney Disease

    Rochester, MN

  10. Predicting Disease Progression in Pediatric Patients With Autosomal Dominant Polycystic Kidney Disease Using Urinary Crystal Burden as a Biomarker

    Rochester, MN

.

Mayo Clinic Footer